retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset retatrutide triple agonist glp-1 gip
Description
Rights and permissions About this article Cite this article Xie, Y., Choi, T
doi: 10.1111/dom.12534
Ushakumari et al183 have expressed reservations regarding The American Society of Anesthesiologists guidelines, highlighting the absence of evidence that discontinuing GLP-1RAs therapy for one day or one week reliably reduces the risk of gastroparesis
One in seven (14%) employers covering GLP-1s for obesity are considering discontinuation due to cost
